Historique
Périodique
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival
(Comparaison des populations à risques dans l'étude EuroSida : initiation d'une thérapie antirétrovirale intensive (HAART), suivi du traitement et taux de guérison)
Auteur(s) :
MOCROFT A. ;
MADGE S. ;
A. M. JOHNSON ;
A. LAZZARIN ;
CLUMECK N. ;
GOEBEL F. D. ;
VIARD J. P. ;
GATELL J. ;
BLAXHULT A. ;
J. D. LUNDGREN
Article en page(s) :
369-378
Refs biblio. :
36
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Français
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Thésaurus mots-clés
SIDA
;
HSH
;
USAGER
;
VOIE INTRAVEINEUSE
;
EPIDEMIOLOGIE
;
COHORTE
;
ETUDE PROSPECTIVE
;
TRAITEMENT
Thésaurus géographique
EUROPE
;
EUROPE DE L'EST
;
AUTRICHE
;
BELGIQUE
;
REPUBLIQUE TCHEQUE
;
DANEMARK
;
FRANCE
;
ALLEMAGNE
;
GRECE
;
HONGRIE
;
IRLANDE
;
ISRAEL
;
ITALIE
;
LUXEMBOURG
;
PAYS-BAS
;
NORVEGE
;
POLOGNE
;
PORTUGAL
;
ESPAGNE
;
SUEDE
;
SUISSE
;
ROYAUME-UNI
Note générale :
Journal of Acquired Immune Deficiency Syndromes, 1999, 22, (4), 369-378
Note de contenu :
graph.
Résumé :
ENGLISH :
BACKGROUND: Concerns have been raised that intravenous drug users may be less likely to start highly active antiretroviral therapy (HAART) and that adherence to therapy may be poor among this group of patients. Given the decreased mortality and incidence of AIDS-defining illnesses among patients with HIV who start HAART, this may lead to a poorer prognosis among intravenous drug users. PURPOSE: To compare homosexual men, intravenous drug users, and heterosexuals in EuroSIDA, a prospective European cohort of 7331 patients with HIV in terms of starting a HAART treatment regimen, immunologic and virologic response to therapy, and survival. METHODS: 6645 patients were included in this analysis. Logistic regression and Cox proportional hazards models were used to investigate the factors associated with use of HAART regimens and survival following recruitment to the EuroSIDA study. RESULTS: In a multivariate logistic regression model, intravenous drug users were significantly less likely to be receiving HAART at recruitment to EuroSIDA (odds ratio [OR], 0.48; 95% confidence interval [CI], 0.37-0.62; p<.0001 when compared with homosexual men. similarly during follow-up intravenous drug users were at a reduced risk of starting haart after adjustment for other factors related to hazard ci p there no differences between heterosexual and patients similar results found within regions europe central northern among those who started significant exposure groups in cd4 lymphocyte count response or virologic haart. survival small but nonsignificant increased death homosexuals conclusions: significantly less likely start did therapy was that groups. death. if continue use commonly than it may result poorer prognosis different spectrum aids-defining illnesses differential long-term clinical needs. s abstract>
ENGLISH :
BACKGROUND: Concerns have been raised that intravenous drug users may be less likely to start highly active antiretroviral therapy (HAART) and that adherence to therapy may be poor among this group of patients. Given the decreased mortality and incidence of AIDS-defining illnesses among patients with HIV who start HAART, this may lead to a poorer prognosis among intravenous drug users. PURPOSE: To compare homosexual men, intravenous drug users, and heterosexuals in EuroSIDA, a prospective European cohort of 7331 patients with HIV in terms of starting a HAART treatment regimen, immunologic and virologic response to therapy, and survival. METHODS: 6645 patients were included in this analysis. Logistic regression and Cox proportional hazards models were used to investigate the factors associated with use of HAART regimens and survival following recruitment to the EuroSIDA study. RESULTS: In a multivariate logistic regression model, intravenous drug users were significantly less likely to be receiving HAART at recruitment to EuroSIDA (odds ratio [OR], 0.48; 95% confidence interval [CI], 0.37-0.62; p<.0001 when compared with homosexual men. similarly during follow-up intravenous drug users were at a reduced risk of starting haart after adjustment for other factors related to hazard ci p there no differences between heterosexual and patients similar results found within regions europe central northern among those who started significant exposure groups in cd4 lymphocyte count response or virologic haart. survival small but nonsignificant increased death homosexuals conclusions: significantly less likely start did therapy was that groups. death. if continue use commonly than it may result poorer prognosis different spectrum aids-defining illnesses differential long-term clinical needs. s abstract>
Affiliation :
Royal Free Centre for HIV Medicine and Dpt of Primary Care and Population Sciences, Royal Free and Univ. College Medical School, Univ. College London, Royal Free Campus, Rowland Hill Str., London NW3 2PF
Royaume-Uni. United Kingdom.
Royaume-Uni. United Kingdom.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |